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Abstract
Background: The epidemiology of liver disease in patients admitted to emergency rooms is
largely unknown. The current study aimed to measure the prevalence of viral hepatitis B and C
infection and pathological laboratory values of liver disease in such a population, and to study
factors associated with these measurements.
Methods: Cross-sectional study in patients admitted to the emergency room of a university
hospital. No formal exclusion criteria. Determination of anti-HBs, anti-HCV, transferrin saturation,
alanine aminotransferase, and obtaining answers from a study-specific questionnaire.
Results: The study included 5'036 patients, representing a 14.9% sample of the target population
during the study period. Prevalence of anti-HBc and anti-HCV was 6.7% (95%CI 6.0% to 7.4%) and
2.7% (2.3% to 3.2%), respectively. Factors independently associated with positive anti-HBc were
intravenous drug abuse (OR 18.3; 11.3 to 29.7), foreign country of birth (3.4; 2.6 to 4.4), non-white
ethnicity (2.7; 1.9 to 3.8) and age t60 (2.0; 1.5 to 2.8). Positive anti-HCV was associated with
intravenous drug abuse (78.9; 43.4 to 143.6), blood transfusion (1.7; 1.1 to 2.8) and abdominal pain
(2.7; 1.5 to 4.8). 75% of all participants were not vaccinated against hepatitis B or did not know
their vaccination status. Among anti-HCV positive patients only 49% knew about their infection and
51% reported regular alcohol consumption. Transferrin saturation was elevated in 3.3% and was
associated with fatigue (prevalence ratio 1.9; 1.2 to 2.8).
Conclusion: Emergency rooms should be considered as targets for public health programs that
encourage vaccination, patient education and screening of high-risk patients for liver disease with
subsequent referral for treatment if indicated.
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Background
Worldwide, about 350 million persons have chronic hep-
atitis B virus (HBV) infection, and about 125 million have
been infected with hepatitis C virus (HCV), putting viral
hepatitis B and C amongst the world's greatest infectious
disease health problems [1-3]. Many patients are not
aware of their chronic disease, and this is also true for
another chronic liver disease, namely hereditary haemo-
chromatosis, which is the most common autosomal reces-
sive genetic disorder in Europe [4]. Viral hepatitis B and C,
and haemochromatosis have in common that they may
lead to liver cirrhosis and subsequently to liver failure and
hepatocellular carcinoma, and that these complications
can be prevented in most patients if diagnosis is made
early and patients receive adequate treatment. Therefore
these liver diseases are attractive candidates for public
health measures aiming at prevention, early diagnosis and
treatment. In this context not only information on the
general population, but also on selected populations with
a potentially higher risk is important. The setting of emer-
gency rooms is particularly attractive for screening
because patients can be directly educated about viral hep-
atitis, and treatment is readily available if necessary. A US
based study determined the prevalence of HBV and HCV
infection in an emergency room patient population in the
early 1990s [5], but no comparable studies were done
recently or in Europe. Likewise no previous studies have
looked at the prevalence of elevated transferrin saturation
(TFS) and its association with clinical symptoms of
haemochromatosis and other liver diseases in such a pop-
ulation. We therefore aimed to study the epidemiology of
these liver diseases in patients admitted to a university
hospital emergency room.
Methods
Setting
The study was conducted in the emergency room (ER) of
the University Hospital Berne where patients are admitted
24 hours per day, 365 days per year. The ER admits about
20'000 patients per year from urban Berne as well as from
the surrounding rural areas. These include any medical,
surgical and subspecialty emergencies, except paediatric,
gynaecologic and obstetric emergencies, which are gener-
ally admitted to other specialised clinics. The study was
approved and supervised by the regional ethics board
(Kantonale Ethikkommission Bern).
Subject recruitment and data collection
The a priori target was to include a representative sample
of 5'000 patients from the population of all patients
admitted to the ER. Patients were recruited between Feb-
ruary 2003 and September 2004. There were no formal
exclusion criteria, but any individual patient could only
be included once. During an initial pilot phase of about
two months we asked only a sample of patients admitted
to the ER to participate in the study (increasing rate from
1 in 10 to 1 in 2 patients, selected by random sampling).
Thereafter all patients were asked to participate in the
study. Upon arrival and admission to the ER, patients
were given a patient information sheet, an informed con-
sent sheet, and a study-specific questionnaire, which was
available in German, French, Italian and English (Table
1). Treating physicians and nurses provided additional
information, answered any study-related questions and
obtained a 10 ml venous blood sample. Demographic
data were collected through the ER's electronic patient
data system.
Table 1: Study-specific patient questionnaire
Questions Answer options
Have you been vaccinated against hepatitis B ? Yes/No/I don't know
Do you have any known hepatitis B infection ? Yes/No
Do you have any known hepatitis C infection ? Yes/No
Have you ever had a yellowing of the skin (known as jaundice) ? Yes/No
Have you ever had a blood transfusion ? Yes/No, if yes until/after 1990 ?
Do you have a tattoo ? Yes/No
Do you have any piercing ? Yes/No
Do you drink alcohol ? Never/1–10/>10 glasses/week
Have you ever taken illegal intravenous drugs ? Yes/No
Do you live with a partner in a steady relationship ? Yes/No
Do you work in the public health services with patient contact ? Yes/No
Have you been suffering from stomach aches without clear cause ? Yes/No
Have you been suffering from tiredness without clear cause ? Yes/No
Have you been suffering from muscle pains without clear cause ? Yes/No
Have you been suffering from joint pains without clear cause ? Yes/No
What is your ethnic origin ? White/Black/Asiatic/other, mixed
Were you born in Switzerland ? Yes/No, if no specifiy:
Do you permanently reside in Switzerland ? Yes/No, if no specifiy:
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Information on the source population
We obtained complete and reliable individual patient
level information (age, sex, country of residence, health
insurance, admission specialty, admission time and date)
on all patients admitted to the ER during the study period
from the hospital's electronic data system. This informa-
tion was used to compare our study population with the
source population, and to standardize prevalence to the
source population.
Laboratory analyses
Anti-HBc antibodies were determined with a diagnostic
kit from Ortho-Clinical Diagnostics (Vitros Immunodiag-
nostic Products Anti-HBcAg Reagent Pack). Anti-HCV
antibodies were determined using a second generation
ELISA (Ortho-Clinical Diagnostics, Vitros Immunodiag-
nostic Products Anti-HCV Reagent Pack), measuring anti-
HCV-C100-3, anti-C22c and anti-C33c. Serum alanine
aminotransferase (ALT) activity, serum iron and total iron
binding capacity were determined using the laboratory's
routine methods. Transferrin saturation (TFS) was calcu-
lated as the ratio of serum iron and total iron binding
capacity.
Data analysis
Unadjusted prevalence was calculated directly, and 95%
confidence intervals were based on a binomial distribu-
tion. For anti-HBc and anti-HCV antibodies prevalence
was also adjusted by direct standardization to the source
population's demographic and admission variables. Uni-
variable (unadjusted) prevalence ratios (PR) were calcu-
lated for several independent variables (factors). When
confounding by other variables was suspected adjusted
relative prevalence rartios were calculated in a restricted
population or as a pooled estimate after stratification over
categories of potentially confounding variables according
to the method of Mantel and Haenszel [6]. Thereafter
multivariable logistic regression was used for the simulta-
neous modelling of independent associations with several
variables. We used log-binomial regression as an alterna-
tive to logistic regression when log-binomial model fitting
could be achieved, in order to estimate prevalence ratios
instead of odds ratios [7]. All analyses were done with
STATA Version 8.2 for MacOS X (Stata Corporation, Col-
lege Station, Texas, USA).
Results
Demographic and admission data
During the study period a total of 33'703 patients were
admitted to the ER; we collected complete data on 5'036
admitted patients, i.e. 14.9 % of the target population.
Demographic and admission data of the study and source
population are presented in Table 2. As shown, the two
populations had overall similar distributions for the avail-
able variables, but study participants were more likely to
be admitted during daytime and during the summer
months, which is most likely attributable to logistic fac-
tors of the study.
Questionnaires
Completed questionnaires were available for all included
patients. Some patients did not answer all questions, but
each question was answered by at least 97%. Particularly
those questions that addressed history of HBV and HCV
infection revealed interesting results: 42% of all included
patients reported that they had not been vaccinated
against HBV, and another 33% did not know whether
they had been vaccinated. Not surprisingly the proportion
of HBV-vaccinated patients decreased with higher age
(Figure 1). 86% of anti-HBc positive patients were not
aware of their previous HBV infection, and 74% men-
tioned no history of jaundice. Only 57% of patients who
reported a previous HBV infection were anti-HBc positive.
Specificity of a positive history of HCV infection obtained
through the study questionnaires was also relatively low
(73% of those who reported a previous HCV infection
were anti-HCV positive), but the proportion of patients
who knew about their previous infection was about three
times higher for HCV than for HBV (49% vs. 14%). Infor-
mation on drinking habits obtained from the question-
naires showed that 10% of men vs. 2.3% of women
reported consumption of more than 10 alcoholic drinks
per week. Among HCV positive patients, 34% had
between 1 and 10, and 16% more than 10 alcoholic
drinks per week. HCV positive patients therefore had a
higher prevalence of having >10 drinks per week (PR 2.5,
95% CI 1.7 to 3.7), and it was not lower in patients who
were aware of their HCV infection (PR 2.7). Importantly,
patients who knew about their HCV infection did not
drink less alcohol. Other results from the questionnaires
are presented in Table 3 along with their associations with
viral hepatitis serology.
Alanine aminotransferase (ALT)
ALT was determined in all but five patients of the study
population. Results are presented in Table 4. As shown,
women had about half the prevalence of elevated ALT
compared to men. There were no pronounced variations
over age categories. In search of the most common causes
of severe ALT elevations, we also reviewed the ER physi-
cians' reports on all 130 studied patients with an ALT
t100 U/l, and derived the most likely cause of their ele-
vated ALT. The most common causes were alcohol con-
sumption (n = 18), infection (n = 17), obstructive
cholestasis (n = 16), pancreatitis (n = 10), drug-induced
(n = 10), abdominal trauma (n = 9) and HCV infection (n
= 8). In 28 patients the reports did not provide any infor-
mation that readily explained their elevated ALT.
BMC Gastroenterology 2007, 7:5 http://www.biomedcentral.com/1471-230X/7/5
Page 4 of 9
(page number not for citation purposes)
Prevalence of anti-HBc and anti-HCV and associated 
factors
Out of 5'036 included patients 336 were anti-HBc, and
135 were anti-HCV positive. 46 patients were positive for
both anti-HBc and anti-HCV. There were 15 borderline
test results for anti-HBc antibodies and 6 for anti-HCV
antibodies. All other patients had negative results. Of the
135 anti-HCV positive patients, 21 were later seen in our
hepatological outpatient clinic, where anti-HCV was
determined with recombinant immunoblot assays
(RIBA), and HCV RNA was measured using polymerase
chain reaction. Nineteen tested both, RIBA and RNA pos-
itive, one RIBA positive and RNA negative, and one RIBA
and RNA negative. In this sample, the predictive value
positive regarding anti-HCV was therefore 20/21 or 95.2%
after confirmatory RIBA. Table 5 shows the resulting
observed prevalences of viral hepatitis serology along with
estimates that were standardised to the demographic and
admission variables of the source population. Anti-HBc
prevalence was substantially higher in patients with a for-
eign country of birth, i.e. 4.5% for patients born in Swit-
zerland vs. 14.4% for those born in any other country,
15.9% for Mediterranean countries, and 20.1% amongst
102 patients born in Italy. Table 3 presents viral serology
results in correlation to questionnaire answers, demo-
graphic and admission characteristics and laboratory
results, and provides univariable prevalence ratios for pos-
itive viral serology. This unadjusted analysis suggested an
association between positive anti-HCV antibodies and tat-
toos (PR = 3.4). However, in a stratified Mantel-Haenszel
analysis that controlled for IVDA as a confounding factor
the adjusted RR was only 1.3 (95% CI 0.9 to 1.7), and also
the alternative approaches of an analysis in a restricted
study population of patients without IVDA and a multi-
variable analysis (Table 6) provided similar results. After
data exploration with stratified and restricted analyses we
selected clinically relevant factors that were associated
with positive viral hepatitis serology in the univariable
Table 2: Demographic and admission data of the study and source population
Study population All ER admissions1
Variable Strata n % n %
All patients 5'036 100 33'703 100
Sex Male 3'018 59.9 19'397 57.6
Female 2'018 40.1 14'299 42.4
Unknown - - 7 0.02
Age (years) < 20 199 4.0 2'380 7.0
20–39 1'890 37.5 12'936 38.4
40–59 1'610 32.0 9'460 28.1
t 60 1'337 26.5 8'927 26.5
Admission specialty Surgery 2'632 52.3 19'730 58.5
Medicine 2'336 46.4 13'973 41.5
Unknown 68 1.3 -2 -
Admission season Nov-Apr 1'693 33.6 14'344 42.6
May-Oct 3'343 66.4 19'359 57.4
Admission time Day (7 am – 7 pm) 4'112 81.7 22'917 68.0
Night (7 pm – 7 am) 856 17.0 10'786 32.0
Unknown 68 1.3 -2 -
Country of residence Switzerland 4'934 98.0 32'853 97.5
Other 102 2.0 850 2.5
Health insurance Basic 3'964 78.7 27'595 81.9
Semi-private 685 13.6 3'650 10.8
Private 165 3.3 970 2.9
Unknown 222 4.4 1'488 4.4
1All admissions to the emergency room of the University Hospital Berne between 26 February 2003 and 20 September 2004 (data obtained via the 
hospital's electronic patient data system)
2There were 68 patients who entered the ER and were included in the study, but where the hospital's data system did not have an entry and 
therefore no information on specialty and time of admission. These are not included in the numbers provided for all admissions.
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analysis and those that were considered as potential con-
founders as independent variables in a logistic regression
model. The resulting adjusted odds ratios for viral serol-
ogy are presented in Table 6.
Transferrin saturation (TFS) and associated factors
TFS was available for all but one patient in the study pop-
ulation. 221 patients had a TFS >45% (4.4%; 95% confi-
dence interval 3.8 to 5.0), 145 >50% (2.9%, 2.4 to 3.4),
and 97 >55% (1.9%, 1.6 to 2.3). Applying sex-specific
limits (>45% in women and >50% in men) prevalence of
elevated TFS was 3.3 % (2.8 to 3.8). We observed no
marked age-dependent differences. Univariable analysis
indicated associations of elevated TFS with elevated ALT
(PR 1.5; 1.0 to 2.1), high alcohol consumption (PR 2.4;
1.6 to 3.6), and fatigue (PR 1.9; 1.4 to 2.7), but not with
positive anti-HCV (PR 1.1; 0.5 to 2.7). Restriction of the
analysis to patients without high alcohol intake, positive
anti-HCV or IVDA (remaining n = 4'457) did not substan-
tially change the association of elevated TFS with fatigue
or ALT. Using the same restrictions we also fitted a log-
binomial regression model with elevated TFS as the
dependent variable and abdominal pain, fatigue, myalgia
and arthralgia (possible symptoms of haemochromato-
sis) as independent variables. This model showed a virtu-
ally identical association of elevated TFS with fatigue (PR
1.9; 1.2 to 2.8), but no significant associations with
abdominal pain, myalgia or arthralgia. Exclusion of non-
white subjects did not substantially change these associa-
tions.
Discussion
The current study presents the first data on prevalence and
associated factors of liver diseases in a large sample of
patients admitted to the emergency room of a European
university hospital. The prevalence of anti-HBc and anti-
Hepatitis B vaccination status according to patient questionnaires over 4 age categoriesFigure 1
Hepatitis B vaccination status according to patient questionnaires over 4 age categories. As shown, knowledge about vaccina-
tion status does not change in relation to age, but the proportion of patients without HBV vaccination increases above the age 
of 40.
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HCV was 6.7% and 2.7%, respectively. Factors independ-
ently associated with positive anti-HBc were IVDA, foreign
country of birth, non-white ethnicity and high age. Posi-
tive anti-HCV was associated with IVDA, blood transfu-
sion and chronic abdominal pain. Patients demonstrated
poor awareness and knowledge of liver disease. Transfer-
rin saturation was elevated in 3.3% and was associated
with chronic fatigue.
The obtained data from a large sample of patients admit-
ted to the ER were essentially complete, plausible, and
generally in accordance with previously available infor-
mation, supporting the overall validity of our study. The
current study also had important limitations: first, we
studied only 14.9% of our target population, and the pos-
sibility of a recruitment bias has to be addressed. There-
fore, we obtained demographic and admission
characteristics on all patients admitted to the ER during
the study period, and a comparison with this information
demonstrated that our study population can be consid-
ered as a reasonably representative sample of the target
population with regard to these variables, and allowed us
to standardise prevalence estimates. Second, we were not
able to perform additional laboratory tests of interest
including HBsAg, anti-HBs, and confirmatory secondary
testing in all anti-HCV positive patients. However, like in
other studies, the primary aim of our study was to deter-
mine past infection with HBV and HCV. Also, further con-
firmatory testing was done in a small sample of anti-HCV
positive patients, and the observed predictive value posi-
tive of 95% suggests that among the 135 anti-HCV posi-
tive patients 129 had a previous HCV infection. Assuming
Table 3: Univariable prevalence ratios (PR) for positive viral hepatitis serology
Negative hepatitis serology (n = 4'592) Anti-HBc positive (n = 336) Anti-HCV positive (n = 135)
Factor n (%)1 n (%)1 PR2 (95%CI) n (%)1 PR2 (95%CI)
Demographics
Female 1'859 (40.5) 117 (34.8) 0.8 (0.6 to 1.0) 44 (33.1) 0.7 (0.5 to 1.0)
Age
d39 1'957 (42.6) 129 (38.4) 1.0 (reference) 59 (43.7) 1.0 (reference)
40–59 1'440 (31.4) 118 (35.1) 1.2 (1.0 to 1.5) 45 (33.3) 1.1 (0.8 to 1.6)
t60 1'195 (26.0) 89 (26.5) 1.1 (0.9 to 1.4) 31 (23.0) 1.0 (0.7 to 1.5)
Admission
Night admission (7 pm–7 am) 625 (15.6) 39 (13.9) 0.9 (0.6 to 1.2) 15 (14.0) 0.9 (0.5 to 1.5)
Nov-April admission 1'557 (33.9) 106 (31.5) 0.9 (0.7 to 1.1) 44 (32.6) 0.9 (0.7 to 1.3)
Medical admission 1'855 (46.3) 153 (54.4) 1.4 (1.1 to 1.7) 55 (40.7) 1.2 (0.8 to 1.7)
(Semi-)private insurance 800 (18.2) 32 (9.9) 0.5 (0.4 to 0.7) 15 (11.8) 0.6 (0.4 to 1.0)
Laboratory results
Elevated ALT 835 (18.2) 91 (27.1) 1.6 (1.3 to 2.0) 56 (41.5) 3.1 (2.2 to 4.3)
Transferrin saturation >45% 200 (4.4) 14 (4.2) 1.0 (0.6 to 1.6) 9 (6.7) 1.5 (0.8 to 3.0)
Questionnaire
History of jaundice 428 (9.5) 88 (26.9) 3.1 (2.5 to 3.9) 39 (29.5) 3.8 (2.6 to 5.4)
Blood transfusion (any time) 945 (21.2) 71 (22.0) 1.0 (0.8 to 1.3) 38 (30.9) 1.6 (1.1 to 2.4)
Blood transfusion before 1990 453 (10.2) 30 (9.3) 0.9 (0.6 to 1.3) 15 (12.2) 1.2 (0.7 to 2.1)
Tattoo 437 (9.6) 43 (12.9) 1.4 (1.0 to 1.9) 37 (27.4) 3.4 (2.3 to 4.9)
Piercing 486 (10.7) 25 (7.5) 0.7 (0.5 to 1.0) 22 (16.4) 1.6 (1.0 to 2.5)
>10 units alcohol per week 294 (6.5) 37 (11.2) 1.7 (1.3 to 2.4) 22 (16.4) 2.7 (1.7 to 4.2)
Intravenous drug abuse 30 (0.7) 39 (11.7) 9.3 (7.4 to 11.8) 55 (40.7) 37.4 (28.6 to 48.8)
Steady relationship 3'221 (70.9) 229 (70.0) 0.9 (0.7 to 1.2) 72 (53.7) 0.5 (0.4 to 0.7)
Professional patient contact 618 (13.6) 41 (12.4) 0.9 (0.7 to 1.2) 14 (10.4) 0.7 (0.4 to 1.3)
Chronic abdominal pain 373 (8.2) 47 (14.2) 1.8 (1.3 to 2.4) 30 (22.7) 3.1 (2.1 to 4.6)
Chronic fatigue 817 (17.9) 84 (25.2) 1.5 (1.2 to 1.9) 45 (33.6) 2.2 (1.6 to 3.2)
Chronic myalgia 467 (10.2) 42 (12.6) 1.2 (0.9 to 1.7) 21 (15.8) 1.6 (1.0 to 2.6)
Chronic arthralgia 568 (12.5) 57 (17.3) 1.4 (1.1 to 1.9) 27 (20.6) 1.8 (1.2 to 2.7)
Ethnicity other than white 244 (5.4) 65 (19.8) 3.6 (2.8 to 4.6) 10 (7.5) 1.4 (0.7 to 2.6)
Not born in Switzerland 926 (20.3) 160 (47.8) 3.2 (2.6 to 3.9) 30 (22.2) 1.1 (0.8 to 1.7)
Not a Swiss resident 92 (2.0) 7 (2.1) 1.0 (0.5 to 2.1) 2 (1.5) 0.7 (0.2 to 2.9)
1If no information was available for individual patients for a certain factor (e.g. admission time), % is calculated as the proportion of all patients with 
available information.
2Unadjusted prevalence ratio of positive viral serology for present vs. absent factor (e.g. first row: prevalence ratio of positive anti-HBc in females vs. 
males), except for age where age d39 is defined as the reference category.
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a 94% sensitivity of the study's enzyme immunoassay [8],
about 137 patients in the tested population would then
have had a previous HCV infection, which is very similar
to the number without these corrections. And although
HCV-RNA was not determined in all patients, one can
expect that approximately 90% of infected patients had a
chronic infection [9]. Third, we were not able to do geno-
typing for mutations associated with haemochromatosis.
Finally, the observed associations are descriptive, and do
not allow causal inferences.
Several studies from different countries have reported
prevalence estimates of viral hepatitis in selected or more
general populations as e.g. in the Italian Dionysos study
[10]. However the only previous study from a developed
country that determined the prevalence of viral hepatitis
in an emergency room population was conducted in Bal-
timore, USA in the early 1990s, i.e. before the introduc-
tion of widespread HBV vaccination programs [5]. There,
the prevalence was 5% for HBsAg, indicating active and
not previous HBV infection, and 18% for anti-HCV. In the
general Swiss population an estimated 3% have been
infected with HBV [11,12], and 0.75% with HCV [13].
Our results therefore indicate that the prevalence of previ-
ous infection is about twice as high for HBV and three
times higher for HCV compared to the general popula-
tion. Possible explanations for the higher prevalence are
medical conditions associated with viral hepatitis that
lead to ER admission and overrepresentation of high-risk
groups such as intravenous drug users, patients not
enrolled in regular health plans and a primarily urban
population. Amongst intravenous drug users, anti-HBc
prevalence was only 11.6% compared to 60–80%
amongst Swiss IVDA cohorts in the 1980s and 20% in the
early 1990s [14,15]. The higher prevalence of previous
HBV infection in immigrants is in accordance with fre-
quent perinatal transmission in countries with high ende-
micity, and with results from a previous Swiss study in
pregnant women [12]. 60% of intravenous drug users
were anti-HCV positive, which is similar to the results of
two Swiss studies published in 1990 and 2000 in IVDA
cohorts [16,17].
The decreasing prevalence of HBV infections in intrave-
nous drug users demonstrates the success of HBV vaccina-
tion programs that target this high-risk group, and
immunization of all adolescents (implemented in Swit-
zerland in 1998), is expected to be eventually highly effi-
cacious in reducing HBV infections in the general
population. However it will require decades until these
measures will reduce the population burden of HBV infec-
tion, and adults at high risk including immigrants are dif-
ficult to reach through national vaccination programs and
public health campaigns. Particularly this high-risk sub-
population is well represented in ER departments. Fur-
ther, 74% of the anti-HCV positive patients admitted to
the ER were less than 60 years old, which is of particular
relevance since treatment with pegylated interferon and
ribavirin should be instituted in patients at risk for late
complications at a young age. Based on a chronic course
in approximately 10% of anti-HBc and 70–80% of anti-
HCV positive patients, about 130 patients with chronic
HBV infection and 350–400 patients with chronic HCV
infection are seen in the studied ER population during
one year. However 42% had not been vaccinated against
HBV, 33% did not know whether they had been vacci-
nated, only less than half of all anti-HCV positive patients
knew about their infection, and half of all anti-HCV posi-
tive patients reported regular alcohol consumption,
which is strongly discouraged as it promotes HCV-related
fibrogenesis [18]. Therefore our results indicate that
Table 5: Observed and standardised prevalences of positive anti-HBc and anti-HCV antibodies in the study population of 5'036 
patients
Prevalence Anti-HBc + % (95% CI) Anti-HCV + % (95% CI)
Observed 6.7 (6.0 to 7.4) 2.7 (2.3 to 3.2)
Standardized to age1 6.5 (5.9 to7.2) 2.6 (2.2 to 3.1)
Standardized to admission variables1 6.1 (5.3 to 6.9) 2.4 (1.9 to 2.8)
1Direct standardisation to distribution of age or admission variables (season, daytime and specialty) of the source population, i.e. all 33'703 patients 
admitted to the emergency room during the study period.
Table 4: Sex-specific distribution of ALT expressed as upper 
limits of normal (ULN) over 4 categories
Men n %
d1× ULN 2'290 75.9
> 1 – 3× ULN 626 20.7
> 3 – 10× ULN 83 2.8
> 10× ULN 19 0.6
Women n %
d1× ULN 1'783 88.3
> 1 – 3× ULN 199 9.9
> 3 – 10× ULN 28 1.4
> 10x ULN 8 0.4
BMC Gastroenterology 2007, 7:5 http://www.biomedcentral.com/1471-230X/7/5
Page 8 of 9
(page number not for citation purposes)
intense efforts to diagnose viral hepatitis and educate
patients in ER have the potential to prevent new infections
and treat complications.
Elevated TFS is an important marker of disease in C282Y
homozygote patients, who account for about 90% of all
clinical cases of haemochromatosis [19,20]. Although the
prevalence of this mutation is known to be about 0.4 to
0.5% in Caucasian populations [4,21], until recently there
has been few data on the penetrance of C282Y in the gen-
eral population, which is critically important for the con-
troversial discussion on the utility of population
screening [22]. In a large international study Adams et al.
reported a prevalence of 0.44% for C282Y homozygotes
in a white primary care population, and amongst those
TFS was >50% in 84% of men and >45% in 73% of
women [21]. Based on this data we would expect 20
C282Y homozygous amongst 4'616 white patients (60%
men) in our study population, and 16 of them with ele-
vated TFS as defined above. We identified 151 patients
with such an elevated TFS amongst 4'616 white patients
(3.3%), which allows us to estimate a specificity of 97%
and a positive predictive value of 11% regarding the iden-
tification of C282Y homozygote patients with elevated
TFS in our study population. This implies that 89% of
patients with an elevated TFS in white patients of our
study population were not C282Y homozygote and there-
fore limits the power and specificity of our results with
regard to haemochromatosis. Other studies in primary
care populations were able to identify patients with
C282Y homozygosity through genetic screening and
reported an association with liver diseases. However, they
also failed to observe an association between C282Y
homozygosity with elevated TFS and the rather non-spe-
cific symptoms of haemochromatosis that are highly prev-
alent in such a population [21,23,24]. Further, our study
had the advantage that patients with high alcohol con-
sumption and HCV infection could be excluded in a sub-
analysis, and the higher prevalence of fatigue in patients
with elevated TFS even within this restricted population
may indicate the presence of other chronic liver diseases
including haemochromatosis and non-alcoholic steato-
hepatitis.
Recent data suggest that even amongst C282Y homozy-
gotes with elevated TFS only a minority will develop frank
Table 6: Adjusted odds ratios for variables associated with positive viral hepatitis serology
Variables1 Odds ratio (95%CI)
Anti-HBc positive
Female 0.8 (0.7 to 1.1)
Age
d39 1.0 (reference)
40–59 1.5 (1.1 to 2.0)
t60 2.0 (1.5 to 2.8)
Intravenous drug abuse 18.3 (11.3 to 29.7)
Ethnicity not white 2.7 (1.9 to 3.8)
Not born in Switzerland 3.4 (2.6 to 4.4)
>10 units alcohol per week 1.5 (1.0 to 2.2)
Anti-HCV positive
Female 0.8 (0.5 to 1.2)
Age
d39 1.0 (reference)
40–59 1.7 (1.0 to 2.9)
t60 1.7 (0.9 to 3.1)
Blood transfusion 1.7 (1.1 to 2.8)
Tattoo 1.7 (0.9 to 3.2)
Piercing 1.1 (0.5 to 2.2)
Intravenous drug abuse 78.9 (43.4 to 143.6)
>10 units alcohol per week 1.1 (0.5 to 2.2)
Steady relationship 0.8 (0.5 to 1.3)
Chronic abdominal pain 2.7 (1.5 to 4.8)
Chronic fatigue 1.2 (0.7 to 2.0)
Chronic arthralgia 1.2 (0.7 to 2.2)
1Multivariable logistic regression models. First column presents all independent variables that were included in the two models with HBV or HCV 
serology as the dependent variable.
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clinical haemochromatosis, and consequently no clear
indication for population-based screening for haemo-
chromatosis has been established [22,24]. Nevertheless,
increased TFS is a useful sign of chronic liver disease
including haemochromatosis and non-alcoholic steato-
hepatitis, and our results confirm that chronic fatigue is a
possible symptom of increased TFS and chronic liver dis-
ease.
Conclusion
We conclude that emergency rooms should be considered
as targets for public health programs that encourage vacci-
nation, patient education and screening of high-risk
patients for liver disease with subsequent referral for treat-
ment if indicated. Future studies may compare our results
with the epidemiology of liver disease in emergency
rooms in other hospitals and countries, and evaluate the
effect of preventive measures.
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